Tag Archives: Cancer News

Common Acid Reflux Drug May Increase Stomach Cancer Risks

Common Acid Reflux Drug Make Increase Stomach Cancer Risks
Common Acid Reflux Drug Make Increase Stomach Cancer Risks

Acid reflux is a relatively common condition that affects a number of people worldwide. Evidence from recent studies suggests that one of the more widely-used acid reflux treatments may increase the risk of stomach cancer.

H. Pylori and Stomach Cancer

Around the globe, stomach cancer is the fifth most common cancer causing the third highest number of cancer-related deaths. H. pylori, a bacterium found in two-thirds of the world’s population, is a major cause of ulcers and a significant risk for stomach cancer.

A 2016 review revealed an association between long-term use of proton pump inhibitors (PPI), a frequently prescribed treatment for acid reflux, and increased risk of cancer. Scientists remained uncertain because the review failed to distinguish between H. pylori and H. pylori-negative participants.

Can Acid Reflux Treatment Increase Stomach Cancer Risk?

In 2017, researchers at the University of Hong Kong set out to find some clarity on the issue. The team separated the study group into PPI users and those using another acid reflux drug known as H2 blockers.

Nearly 64,000 participants began with a seven-day course of triple therapy, which involves use of a PPI with two antibiotics to eradicate H. pylori. Results showed that, even in the absence of H. pylori, PPI usage more than doubled risk of stomach cancer while usage of H2 blockers demonstrated no increased risk.

Immunotherapy for Cancer: A Non-Toxic, Integrative Program

At Issels®, our individually created immunotherapy for cancer treatments have helped patients with stomach cancer and other therapy-resistant forms. Contact us for more information about the legacy of our namesake, Dr. Josef M. Issels, and our non-toxic immunotherapy programs.

MSK1 Protein Research May Answer Why Some Breast Cancer Stays Dormant

MSK1 Protein Research May Answer Why Some Breast Cancer Stays Dormant
MSK1 Protein Research May Answer Why Some Breast Cancer Stays Dormant

Scientists have long been puzzled by the process of metastasis in breast cancer and what causes the cells to lie dormant. A recent study revealed valuable information that can pay off with more effective breast cancer treatment.

Understanding Latency in Breast Cancer Metastases

Researchers at the Institute for Research in Biomedicine (IRB) in Barcelona set out to study estrogen-positive (ER+) breast tumors that feature long periods of asymptomatic latency. This type accounts for 80 percent of breast cancer cases.

The Barcelona team identified a protein kinase called MSK1 as the primary regulator of dormant metastases. After examining clinical samples from patients, the researchers determined that ER+ breast cancer tumors that don’t express MSK1 tend to suffer earlier relapse, while those that do express MSK1 experience later metastases.

Breakthrough in Breast Cancer Treatment

Head researcher Roger Gormis explained that little was previously known about why breast cancer metastasis time varies from one patient to another. Study results also showed that suppressing MSK1 causes faster-growing cancer cells that have a greater chance of metastasizing.

Benefits of the study are two-fold:

– Doctors may be better able to identify patients who are more likely to relapse and adjust treatment protocol.

– Scientists may be able to develop a treatment that mimics the role of MSK1, thereby keeping metastasis dormant for as long as possible.

Effective Late-Stage Cancer Treatment at Issels®

Our non-toxic, personally tailored immunotherapy programs have effectively treated patients with late-stage and therapy resistant cancer of all forms, including breast, lung and colorectal. Contact us to learn more about why Issels® is the leader in state-of-the-art immunotherapy treatments.

Protein Blocking May Play a New Role in New Testicular Cancer Treatment

Protein Blocking May Play a New Role in New Testicular Cancer Treatment
Protein Blocking May Play a New Role in New Testicular Cancer Treatment

What options does a patient have when traditional forms of cancer treatment fail? In the case of testicular cancer, scientists found a new combination of treatments that may provide added hope.

Overcoming Resistance to Cancer Treatment

Testicular germ cell tumors are a form of cancer found most commonly in younger men. A research team at the Institute of Cancer Research in London, encouraged by earlier work at the facility, examined the function of a certain type of protein in the development of testicular cancer.

The team focused specifically on insulin growth factor receptor-1. They discovered that IGF1R, as the protein is also called, was more active in some testicular cancer cells as opposed to normal tissue. Using chemical inhibitors, the researchers were able to deplete the supply of IGF1R or curtail its activity, thereby reducing cell growth.

In addition, blocking IGF1R activity in previously drug-resistant cells made them more receptive to platinum-based chemotherapy. The team is hopeful that the two treatments, used in tandem, will be more successful in killing testicular cancer cells.

What Does the Future Hold?

Receptor tyrosine kinases, the class of proteins that includes IGF1R, are linked to cell growth and division in several other types of cancer. Clinical trials have tested the use of IGF1R in hopes that they may have positive results in other applications.

Effective Cancer Treatment for Therapy-Resistant Tumors

For decades, Issels® has been helping patients with advanced and therapy-resistant cancer achieve long-term remission. Contact us to learn how we are continuing the legacy of our founder, Dr. Josef M. Issels, who was a pioneer in the field of immunotherapy for cancer.

Adoptive Cell Transfer a Natural Immunotherapy for Cancer

Adoptive Cell Transfer a Natural Immunotherapy for Cancer
Adoptive Cell Transfer a Natural Immunotherapy for Cancer09

Scientists are excited about immunotherapy for cancer because it supplements a patient’s own natural defenses of the immune system. Thanks to a recent study, researchers have made a discovery that could lead to more effective immunotherapy treatments.

What Is Adoptive Cell Transfer?

Adoptive cell transfer, one of the primary forms of immunotherapy for cancer, involves extracting a patient’s T-cells, which are a form of white blood cells that attack foreign invaders in the system. After engineering the T-cells to target the specific proteins in cancer cells, they are injected back into the patient.

While adoptive cell transfer has been successful in treating blood and bone marrow cancers, it’s been less effective with solid tumors. A team from The Scripps Research Institute and the University of California, San Diego set out to find a better way to program the T-cells.

Unleashing the Power of T-Cells

The researchers zeroed in on a protein known as Runx3, which appeared to specifically direct T-cells to solid tumors. During testing on animal models, it was found that overexpression of Runx3 led to delayed tumor growth and longer life.

Matthew Pipkin of Scripps said that Runx3 works on chromosomes within T-cells, enabling them to focus on killing tumor cells. Pipkin was hopeful that their discovery would pave the way for improving the effectiveness of adoptive cell transfer on solid tumors.

Issels®: The Leader in Immunotherapy for Cancer

Our proprietary immunobiologic core protocols are specifically designed to meet each patient’s individual needs. Contact us to learn more about our record of helping patients achieve and sustain long-term remission.

Some Cancers Cloak Themselves from the Immune System’s Discovery

Some Cancers Cloak Themselves from the Immune System's Discovery
Some Cancers Cloak Themselves from the Immune System’s Discovery

Immunotherapy cancer treatment is designed to aid the body’s immune system in recognizing and attacking tumor cells. Scientists are finally uncovering clues as to how cancer cells are able to evade detection by the body’s natural defenses.

How Cancer Blocks the Immune System

The first steps were taken in 2009 by a team headed up by Dr. Irving Weissman, director of Stanford’s Institute for Stem Cell Biology and Regenerative Medicine. Their research discovered that some cancer cells are able to emit a “don’t eat me” signal.

High levels of CD47, a transmembrane protein, are found on the surface of more aggressive cancer cells. CD47 then binds with another protein called SIRPalpha on the surface of macrophages, a type of white blood cell, inhibiting their ability to attack cancer cells.

In 2017, Dr. Weissman’s team published the results of a recent study that identified another protein that interferes with macrophage activity. When MHC class 1 binds with a protein known as LILRB1, it’s resistant to an antibody that has been used successfully to counteract CD47 in tests on mice with cancer.

Applications for Immunotherapy Cancer Treatment

Cancer research is complicated by the fact that different types have different “fingerprints.” The studies conducted by Dr. Weissman’s team are helping scientists learn more about strategies to “outwit” cancer cells and their ability to avoid detection.

Issels®: Pioneering Immunotherapy Cancer Treatment

Our founder, Dr. Josef Issels, was ahead of his time in focusing on the immune system as the key to defeating advanced cancer. Contact us to learn more about how we are continuing his legacy of helping patients achieve long-term remission.

Molecularly Targeted Therapy Emerges As Another Possible Cancer Treatment

Molecularly Targeted Therapy Emerges As Another Possible Cancer Treatment
Molecularly Targeted Therapy Emerges As Another Possible Cancer Treatment

The problem with traditional cancer treatments is that they attack healthy cells along with diseased cells, which results in serious side effects such as fatigue and hair loss. Doctors are encouraged by the success of a new cancer treatment that zeroes in on the cancer cells.

The “Next Revolution in Cancer Therapy”

Molecularly targeted therapy is being hailed as the next big step in cancer treatment. These new drugs are designed at the molecular level to attack the diseased cells of a specific type of cancer. In addition, they can identify specific molecules that are part of specific cancers.

The drugs are created by a process that is the reverse of how most cancer drugs are developed. Scientists identify an abnormal molecule that’s unique to a particular type of cancer, then design a drug that shuts down its activity.

Gleevec: Paving the Way

Novartis Pharmaceuticals has developed Gleevec, also known as STI571, which is leading the way for molecularly targeted therapy. Gleevec is used for chronic myeloid leukemia, or CML, which is a rare form of the disease characterized by excessive production of white blood cells.

Researchers discovered that Gleevec is also effective against GIST, a rare gastrointestinal cancer. GIST features a unique enzyme related to the original target enzyme in CML.

State-of-the-Art Cancer Treatment at Issels®

Gene-targeted therapies, including Gleevec, Tamoxifen and Avastin, are a significant part of our personalized treatment programs. Issels® also uses non-toxic immunotherapy treatments that boost the immune system’s ability to target tumor cells.

Contact us today for more information about our decades of success in helping patients achieve long-term remission.